How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

15,634 results for

Squamous Cell Carcinoma of the Skin

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

161. Squamous Cell Carcinoma in Perineal, Perianal, and Gluteal Hidradenitis Suppurativa: Experience in 12 Patients. (Abstract)

. Seven of 12 patients followed had postoperative SCC recurrence. Squamous cell carcinoma caused death despite wide surgical excision in these 7 patients. Of the remaining 5 patients, 4 are unknown and 1 who did not recur had an in situ SCC (Bowen disease carcinoma). Squamous cell carcinoma was not associated with high-risk or low-risk HPV.Invasive SCC arising in HS carries a high risk of death. (...) Squamous Cell Carcinoma in Perineal, Perianal, and Gluteal Hidradenitis Suppurativa: Experience in 12 Patients. Few reports describe squamous cell carcinoma (SCC) arising in hidradenitis suppurativa (HS).The 2 objectives were (1) to describe the clinical characteristics, pathologic findings, and postoperative outcomes of SCC in HS and (2) to assess whether human papillomavirus (HPV) is involved in the pathogenesis.Cases of SCC in HS were identified through institutional medical records (1976

2018 Dermatologic Surgery

162. Maintenance Avelumab Immunotherapy in Patients With Locally Advanced or Metastatic Squamous Cell Penile Carcinoma

as this is a maintenance study. After inclusion, Avelumab will be administered at a dose of 10 mg/kg, at a frequency of once every 2 weeks with appropriate supportive care. Condition or disease Intervention/treatment Phase Penile Cancer Penile Neoplasms Penile Squamous Cell Carcinoma Drug: Avelumab Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (Clinical Trial) Estimated Enrollment : 32 participants Intervention Model: Single Group Assignment Masking: None (Open Label (...) by Centre Hospitalier Universitaire de Besancon: Immunotherapy Penile Cancer Penile Squamous Cell Carcinoma Avelumab maintenance Additional relevant MeSH terms: Layout table for MeSH terms Carcinoma Carcinoma, Squamous Cell Penile Neoplasms Neoplasms, Glandular and Epithelial Neoplasms by Histologic Type Neoplasms Neoplasms, Squamous Cell Genital Neoplasms, Male Urogenital Neoplasms Neoplasms by Site Genital Diseases, Male Penile Diseases Antibodies, Monoclonal Immunologic Factors Physiological Effects

2018 Clinical Trials

163. Trial of MG1-MAGEA3 With Ad-MAGEA3 and Pembrolizumab in Patients With Previously Treated Metastatic Melanoma or Cutaneous Squamous Cell Carcinoma

with Metastatic Melanoma or Cutaneous Squamous Cell Skin Cancer that has failed prior standard of care treatments. Upon determination of a Maximum Tolerated Dose (MTD) or Maximum Feasible Dose (MFD) the study will be expanded into up to 24 additional Metastatic Melanoma patients. Condition or disease Intervention/treatment Phase Metastatic Melanoma Squamous Cell Skin Carcinoma Drug: Ad-MAGEA3 Drug: MG1-MAGEA3 Drug: Pembrolizumab Drug: Cyclophosphamide Phase 1 Detailed Description: This is a Phase 1b open (...) ), a tumor antigen Drug: MG1-MAGEA3 MG1 Maraba oncolytic virus expressing Melanoma-associated antigen 3 (MAGEA3), a tumor antigen Drug: Pembrolizumab monoclonal antibody; checkpoint inhibitor of PD1 Other Name: Keytruda Outcome Measures Go to Primary Outcome Measures : Safety of Ad/MG1-MAGEA3 administration in Melanoma or Squamous Cell Skin Carcinoma [ Time Frame: 6 months ] Safety will be determined by assessing the severity and frequency of treatment emergent Adverse Events and clinical laboratory

2018 Clinical Trials

164. Safety and Efficacy Study of PRV111 in Subjects With Oral Squamous Cell Carcinoma

to the standard of care tumor resection. Condition or disease Intervention/treatment Phase Oral Squamous Cell Carcinoma Drug: PRV111 (Cisplatin Transmucosal System) Phase 1 Phase 2 Detailed Description: Up to 31 subjects diagnosed with oral squamous cell carcinoma will receive one application of a permeation enhancer and 2, 3 or 5 treatment applications of a Cisplatin drug-loaded patch to the tumor site at each of 4 treatment visits. These 4 treatment visits will be scheduled to occur during the 3 weeks prior (...) Update Posted : December 3, 2018 See Sponsor: Privo Technologies Information provided by (Responsible Party): Privo Technologies Study Details Study Description Go to Brief Summary: Up to 31 subjects diagnosed with oral squamous cell carcinoma will receive one application of a permeation enhancer and 2, 3 or 5 treatment applications of a Cisplatin drug-loaded patch to the tumor site at each of 4 treatment visits. These 4 treatment visits will be scheduled to occur during the 3 weeks prior

2018 Clinical Trials

165. A Study of mDCF in Combination or Not With Atezolizumab in Advanced Squamous Cell Anal Carcinoma

of randomization (14 days if radiotherapy of bone metastases) Diagnosis of additional malignancy within 3 years prior to the randomization with the exception for curatively treated basal cell carcinoma of the skin and/or curatively resected in situ cervical or breast cancer, Any medical or psychiatric condition or disease, which would make the patient inappropriate for entry into this study, Current participation in a study of an investigational agent or in the period of exclusion, Pregnancy, breast-feeding (...) : Squamous cell carcinoma of the anal canal (SCCA) is a rare disease, its incidence increases worldwide and no standard therapy is currently available to treat metastatic or relapsing cases. SCCA is mostly induced by human papillomavirus (HPV) infections with HPV-related oncoproteins (E6 and E7) expressed in more than 90% of cases. Based on the preliminary results of the Epitope-HPV02 study and although it provide proof of concept data on taxane-based chemotherapy efficacy in SCCA, complete responses

2018 Clinical Trials

166. Durvalumab, Tremelimumab and Stereotactic Body Radiation Therapy in Treating Participants With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma

, tremelimumab and stereotactic body radiation therapy in treating patients with head and neck squamous cell carcinoma that has come back or that has spread to other places in the body. Immunotherapy with monoclonal antibodies, such as durvalumab and tremelimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread Stereotactic body radiation therapy uses special equipment to position a patient and deliver radiation to tumors with high (...) precision. This method can kill tumor cells with fewer doses over a shorter period and cause less damage to normal tissue. Giving durvalumab, tremelimumab, and stereotactic body radiation therapy may work better in treating patients with recurrent or metastatic head and neck squamous cell carcinoma. Condition or disease Intervention/treatment Phase Metastatic Head and Neck Squamous Cell Carcinoma Recurrent Head and Neck Squamous Cell Carcinoma Biological: Durvalumab Other: Laboratory Biomarker Analysis

2018 Clinical Trials

167. Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma

in patients with locally advanced or metastatic ESCC who had failed to cisplatin- or oxaliplatin-based first-line chemotherapy. The hypotheses are as follows: H0: the percentage of patients alive at 9 months of 40% is not useful. H1: the percentage of patients alive at 9 months of 60% is expected. Condition or disease Intervention/treatment Phase Squamous Cell Carcinoma Drug: Onivyde Drug: Paclitaxel Phase 2 Detailed Description: Principal objective: • To evaluate the survival of patients at 9 months (...) . For general information, Layout table for eligibility information Ages Eligible for Study: 18 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion Criteria: Histologically proven metastatic oesophageal squamous cell carcinoma Patient in failure with 1st-line treatment with oxaliplatin or cisplatin. Patients presenting with resectable disease treated with surgery or neoadjuvant or adjuvant chemotherapy with oxaliplatin or cisplatin

2018 Clinical Trials

168. Afatinib and Pembrolizumab for Head and Neck Squamous Cell Carcinoma (ALPHA Study)

: October 4, 2018 Last Update Posted : October 4, 2018 See Sponsor: National Taiwan University Hospital Information provided by (Responsible Party): National Taiwan University Hospital Study Details Study Description Go to Brief Summary: The primary objectives of the trial is to examine the toxicities and efficacies of afatinib and pembrolizumab for recurrent and/or metastatic head and neck squamous cell carcinoma. Condition or disease Intervention/treatment Phase Head and Neck Neoplasms Drug: Afatinib (...) : 20 Years and older (Adult, Older Adult) Sexes Eligible for Study: All Accepts Healthy Volunteers: No Criteria Inclusion criteria Histologically confirmed squamous cell carcinoma of oral cavity, oropharynx, hypopharynx, or larynx. The recurrent disease is not suitable for curative surgery or definitive chemoradiation, and/or metastatic diseases which are not amenable to surgery and/or curative radiotherapy. Tumor progression or recurrence within 6 months of last dose of platinum therapy

2018 Clinical Trials

169. Abemaciclib + Nivolumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma That Progressed or Recurred Within Six Months After Platinum-based Chemotherapy

will be performed on tumor tissue and blood obtained before and during treatment with abemaciclib and nivolumab. These biomarker data will be correlated with survival and tumor response to abemaciclib and nivolumab. Condition or disease Intervention/treatment Phase Head and Neck Squamous Cell Carcinoma Drug: Abemaciclib Drug: Nivolumab Procedure: Tumor biopsy Procedure: Peripheral blood Other: EORTC QLQ-30 Phase 1 Phase 2 Study Design Go to Layout table for study information Study Type : Interventional (...) of completely resected skin carcinoma or other cancers with a low risk of recurrence. Ongoing toxicity attributed to prior anti-cancer therapy that is > grade 1, except alopecia, anemia, fatigue or rash. Active central nervous system metastases: defined as currently receiving radiation therapy to metastatic CNS disease. Once radiation therapy is completed, patients with CNS disease are eligible if they meet all other criteria for enrollment. History of severe allergic reactions attributed to agents used

2018 Clinical Trials

170. Afatinib and Nivolumab as Treatment for Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck

) and nivolumab (OPDIVO®) and to assess the anti-cancer effects of this combination of drugs when used to treat patients with advanced head and neck cancers that did not respond to previous treatments. Condition or disease Intervention/treatment Phase Recurrent Squamous Cell Carcinoma of the Head or Neck Metastatic Squamous Cell Carcinoma of the Head or Neck Squamous Cell Carcinoma Drug: Nivolumab Drug: Afatinib Phase 1 Detailed Description: Primary Objectives: Phase I: To determine dose limiting toxicities (...) (DLTs) and maximum tolerated dose (MTD) of afatinib when given in combination with nivolumab for subjects with recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck not previously treated with immunotherapy Phase IB: To determine long term safety of afatinib in combination with nivolumab when administered to subjects with recurrent/metastatic Squamous Cell Carcinoma of the Head and Neck who had experienced disease progression during or after platinum- and cetuximab-based chemotherapy

2018 Clinical Trials

171. Case Report: Squamous Cell Carcinoma Referred for Mohs Surgery Found to be Cutaneous Leishmaniasis. Full Text available with Trip Pro

Case Report: Squamous Cell Carcinoma Referred for Mohs Surgery Found to be Cutaneous Leishmaniasis. Chronic skin lesions constitute a clinical diagnostic challenge. We report the case of a patient whose facial lesion was histopathologically compatible with squamous cell carcinoma and hence programmed for Mohs surgery. However, review of the clinical and epidemiological history led to laboratory diagnosis of cutaneous leishmaniasis, treatment with miltefosine, and complete resolution

2018 American Journal of Tropical Medicine & Hygiene

172. Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity Full Text available with Trip Pro

Preclinical comparison of proteasome and ubiquitin E1 enzyme inhibitors in cutaneous squamous cell carcinoma: the identification of mechanisms of differential sensitivity Proteasome inhibitors have distinct properties and the biochemical consequences of suppressing ubiquitin E1 enzymes and the proteasome differ. We compared the effects of the proteasome inhibitors bortezomib, ixazomib and carfilzomib and the ubiquitin E1 enzyme inhibitor MLN7243/TAK-243 on cell viability and cell death (...) in normal keratinocytes and cutaneous squamous cell carcinoma (cSCC) cell lines. The effects of both a pulse of treatment and more extended incubation were investigated. This is relevant to directly-delivered therapy (topical treatment/intratumoral injection) where the time of exposure can be controlled and a short exposure may better reflect systemically-delivered inhibitor pharmacokinetics. These agents can selectively kill cSCC cells but there are variations in the pattern of cSCC cell line

2018 Oncotarget

173. WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma Full Text available with Trip Pro

WNT ligands control initiation and progression of human papillomavirus-driven squamous cell carcinoma Human papillomavirus (HPV)-driven cutaneous squamous cell carcinoma (cSCC) is the most common cancer in immunosuppressed patients. Despite indications suggesting that HPV promotes genomic instability during cSCC development, the molecular pathways underpinning HPV-driven cSCC development remain unknown. We compared the transcriptome of HPV-driven mouse cSCC with normal skin and observed higher (...) amounts of transcripts for Porcupine and WNT ligands in cSCC, suggesting a role for WNT signaling in cSCC progression. We confirmed increased Porcupine expression in human cSCC samples. Blocking the secretion of WNT ligands by the Porcupine inhibitor LGK974 significantly diminished initiation and progression of HPV-driven cSCC. Administration of LGK974 to mice with established cSCC resulted in differentiation of cancer cells and significant reduction of the cancer stem cell compartment. Thus, WNT/β

2018 Oncogene

174. Perineal squamous cell carcinoma arising from an epidermal cyst: a case report Full Text available with Trip Pro

Perineal squamous cell carcinoma arising from an epidermal cyst: a case report Epidermal cysts and squamous cell carcinomas (SCCs) are common skin lesions. However, a malignant change in an epidermal cyst is very rare. The incidence of a malignant change from an epidermal cyst to cutaneous SCC is 0.011-0.045%. In particular, malignant transformation of an epidermal cyst in the perineum is extremely rare. To date, three cases have been reported in the English literature.We report a case of 51 (...) -year-old male with an approximately 15-cm perineal mass. This mass started to grow suddenly 4 months previously and caused great discomfort in the perineum due to the large size. The patient underwent excision of the mass with a negative margin. Histopathological analysis confirmed a microinvasive SCC arising from a proliferating epidermoid cyst.Even if benign tumors are suspected, a change in size, pain, ulceration, or discharge should indicate the need for surgical resection due

2018 World journal of surgical oncology

175. Use of dermatoscopy in the detection of squamous cell carcinoma in a patient with recessive dystrophic epidermolysis bullosa Full Text available with Trip Pro

Article 2018 07 31 United States Dermatol Pract Concept 101585990 2160-9381 dermoscopy nonmelanoma skin cancer severe generalized recessive dystrophic bullous epidermolysis squamous cell carcinoma Competing interests: The authors have no conflicts of interest to disclose. 2017 12 05 2018 03 06 2018 8 18 6 0 2018 8 18 6 0 2018 8 18 6 1 epublish 30116669 10.5826/dpc.0803a15 dp0803a15 PMC6092081 Eur J Dermatol. 2015 Apr;25 Suppl 1:30-2 26083672 Br J Dermatol. 2016 Jan;174(1):56-67 26302137 Clin Exp (...) Use of dermatoscopy in the detection of squamous cell carcinoma in a patient with recessive dystrophic epidermolysis bullosa 30116669 2018 11 14 2160-9381 8 3 2018 Jul Dermatology practical & conceptual Dermatol Pract Concept Use of dermatoscopy in the detection of squamous cell carcinoma in a patient with recessive dystrophic epidermolysis bullosa. 227-230 10.5826/dpc.0803a15 Toncic Ruzica Jurakic RJ Department of Dermatology and Venereology, University Hospital Centre Zagreb, University

2018 Dermatology practical & conceptual

176. Outdoor work as a risk factor for high-grade cutaneous squamous cell carcinoma of the head and neck Full Text available with Trip Pro

Outdoor work as a risk factor for high-grade cutaneous squamous cell carcinoma of the head and neck While it is clear that individuals with outdoor occupations are at a significantly greater risk of developing cutaneous squamous cell carcinoma (cSCC), no previous studies have investigated the potential association between the tumour grade and occupation in this patient population.To assess occupation as a risk factor for the development of high-grade cSCC. Secondarily, to determine (...) aggressive cancers. These findings provide additional support for classifying cSCC as an occupational disease. Early education about the dangers of sun exposure during the first years of school is essential to minimize the risks of developing high-grade skin cancer.

2018 Advances in Dermatology and Allergology/Postȩpy Dermatologii i Alergologii

177. Activation and overexpression of the aryl hydrocarbon receptor contribute to cutaneous squamous cell carcinomas: an immunohistochemical study Full Text available with Trip Pro

Activation and overexpression of the aryl hydrocarbon receptor contribute to cutaneous squamous cell carcinomas: an immunohistochemical study In vitro studies showed that the aryl hydrocarbon receptor (AHR) contributed to the development of cutaneous squamous cell carcinomas, but supporting clinical data are lacking.Immunohistochemical analysis was used to detect the expression of AHR, CYP1A1, EGFR, and Ki-67 in 10 actinic keratosis (AK) cases, 10 Bowen disease (BD) cases, 20 cutaneous squamous (...) cell carcinoma (cSCC) cases and 20 normal skin samples. H-scores were used to assess the immunoreactivity.Weak positive AHR immunoreactivity was found in all normal skin samples, while strong positive AHR immunoreactivity was found in atypical squamous proliferation (AK, BD and cSCC) cases. H-scores and the rate of strong immunostaining of the atypical squamous proliferation cases were higher than those of normal controls (p < 0.01). Nuclear expression of AHR was higher in atypical squamous

2018 Diagnostic pathology

178. Gene expression imputation identifies candidate genes and susceptibility loci associated with cutaneous squamous cell carcinoma Full Text available with Trip Pro

Gene expression imputation identifies candidate genes and susceptibility loci associated with cutaneous squamous cell carcinoma Cutaneous squamous cell carcinoma (cSCC) is a common skin cancer with genetic susceptibility loci identified in recent genome-wide association studies (GWAS). Transcriptome-wide association studies (TWAS) using imputed gene expression levels can identify additional gene-level associations. Here we impute gene expression levels in 6891 cSCC cases and 54,566 controls

2018 Nature communications

179. A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes Full Text available with Trip Pro

A Natural History of Actinic Keratosis and Cutaneous Squamous Cell Carcinoma Microbiomes Cutaneous squamous cell carcinoma (SCC) is the second-most-common cancer in Australia. The majority of SCCs progress from premalignant actinic keratosis (AK) lesions that form on chronically sun-exposed skin. The role of skin microbiota in this progression is not well understood; therefore, we performed a longitudinal microbiome analysis of AKs and SCCs using a cohort of 13 SCC-prone immunocompetent men (...) , suggesting their specific involvement with AK-to-SCC progression. If a causative link exists between certain S. aureus-like OTUs and SCC etiology, therapeutic approaches specifically targeting these bacteria could be used to reduce SCC.IMPORTANCE Actinic keratosis (AK) and cutaneous squamous cell carcinoma (SCC) are two of the most common dermatologic conditions in Western countries and cause substantial morbidity worldwide. The role of human papillomaviruses under these conditions has been well studied

2018 mBio

180. Successful development of squamous cell carcinoma and hyperplasia in RGEN-mediated p27 KO mice after the treatment of DMBA and TPA Full Text available with Trip Pro

) and 12-O-tetradecanoylphorbol-13-acetate (TPA)(DT) for 5 months. The target region (544~571 nt) in exon I of the p27 gene was successfully disrupted in p27 (IΔ) KO mice using the RGEN-induced non-homologous end joining (NHEJ) technique. After DT exposure for 5 months, a few solid tumors (identified as squamous cell carcinoma) developed on the surface of back skin of DT-treated p27 (IΔ) KO mice. Also, squamous cell hyperplasia with chronic inflammation was detected in the skin dermis of DT-treated p27 (...) (IΔ) KO mice, while the Vehicle+p27 (IΔ) KO mice and WT mice maintained their normal histological skin structure. A significant increase was observed in the expression levels of tumor suppressor protein (p53), apoptotic proteins (Bax, Bcl-2 and Caspase-3) and cell-cycle regulator proteins (Cyclin D1, CDK2 and CDK4) in the skin of DT-treated p27 (IΔ) KO mice, although their enhancement ratio was varied. Taken together, the results of the present study suggest that squamous cell carcinoma

2018 Laboratory animal research

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>